Skip to main content
. Author manuscript; available in PMC: 2023 Apr 14.
Published in final edited form as: Clin Cancer Res. 2022 Oct 14;28(20):4551–4564. doi: 10.1158/1078-0432.CCR-22-1128

Figure 1.

Figure 1.

Bomedemstat treatment upregulates NOTCH and suppresses ASCL1 targets in human and murine SCLC models. A, Immunoblot analysis of FHSC04 PDX model tumors after treatment with vehicle or bomedemstat (25 mg per kg per day). B, Survival of murine SCLC (mSCLC) cell lines RP-116 and RP-48 treated with bomedemstat for 96 hours, relative to cells treated with DMSO (mean±SEM of three independent replicates), as determined by CellTiterGlo reagent. C, Immunoblot analysis of mSCLC cell lines after exposure to bomedemstat (1 μM) or DMSO for 96 hours. D, Differential gene expression analysis of RP-116, RP-48, and G8545 mSCLC cell lines after exposure to bomedemstat (1 μM) or DMSO for 96 hours, showing fold-change in bomedemstat-treated cells relative to DMSO. Selected genes of interest with respect to neuroendocrine differentiation and immune cell recruitment are highlighted. The −log10(FDR) is artificially capped at 25 for display purposes. E, Gene set enrichment analysis-derived running Enrichment Score (ES) of a custom gene set comprising 141 ASCL1 target genes in RP-116, RP-48, and G8545 mSCLC cell lines.